Research Programs Discontinued
0
Drugs Discontinued
0
since passage of the Inflation Reduction Act
News Updates
Incubate’s Investment Tracker measures the impacts of the Inflation Reduction Act’s healthcare provisions on the life sciences ecosystem, with special attention to the impacts of the small molecule penalty.
Date
Disease Area
Drug Type
Announcement Type
Company Size
Search
February 15, 2026
Elpiscience (Suzhou) Biopharma, Ltd.
Orphan Drug Designation
treatment of desmoid tumors
Disease Area: Rare Disease
February 15, 2026
New York University, on behalf of NYU Grossman School of Medicine
Orphan Drug Designation
treatment of primary CoQ10 deficiency
Disease Area: Rare Disease
February 14, 2026
InGel Therapeutics Inc.
Orphan Drug Designation
treatment of retinitis pigmentosa
Disease Area: Rare Disease
February 13, 2026
Bristol Myers Squibb
Orphan Drug Designation
Lawrenceville, NJ
10,001-50,000 employees
treatment of follicular lymphoma
Disease Area: Rare Disease
February 13, 2026
Zomagen Biosciences Ltd, a wholly owned subsidiary of Ventyx Biosciences, Ltd.
Orphan Drug Designation
treatment of pericarditis
Disease Area: Rare Disease
February 12, 2026
FBD Biologics Limited
Orphan Drug Designation
treatment of gastric cancer
Disease Area: Rare Disease
February 12, 2026
NorthSea Therapeutics B.V.
Orphan Drug Designation
treatment of intestinal failure associated liver disease
Disease Area: Rare Disease
February 11, 2026
Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
Orphan Drug Designation
treatment of pancreatic cancer
Disease Area: Rare Disease
February 11, 2026
MeiraGTx UK II Ltd
Orphan Drug Designation
treatment of inherited retinal dystrophy due to GUCY2D gene mutations
Disease Area: Rare Disease
February 10, 2026
2A Biosciences, Inc.
Orphan Drug Designation
treatment of neurotrophic keratopathy
Disease Area: Rare Disease